Skip to main content

Biomarkers for cancer immunotherapy

This Biomarker Research thematic series is currently open for submissions. Research studies and reviews on biomarkers for diagnosis, prognosis, and targeted therapy for cancer immunotherapy are welcome to the series. Novel and/or major advances in methodologies and materials for biomarker research will be also be considered. 

To ensure publication in 2021, the submission deadline for all manuscripts is September 30. Submissions should be made via the journal's Editorial Manager.

Biomarkers for cancer immunotherapy © © wildpixel / Getty Images / iStock

  1. Cell therapy has evolved rapidly in the past several years with more than 250 clinical trials ongoing around the world. While more indications of cellular therapy with chimeric antigen receptor – engineered T ...

    Authors: Hongtao Liu, Chongxian Pan, Wenru Song, Delong Liu, Zihai Li and Lei Zheng

    Citation: Biomarker Research 2021 9:62

    Content type: Review

    Published on:

  2. Neoantigens, a type of tumor-specific antigens derived from non-synonymous mutations, have recently been characterized as attractive targets for cancer immunotherapy. Owing to the development of next-generatio...

    Authors: Xuan Zhao, Xiaoxin Pan, Yi Wang and Yi Zhang

    Citation: Biomarker Research 2021 9:61

    Content type: Review

    Published on:

  3. SMAD1, a central mediator in TGF-β signaling, is involved in a broad range of biological activities including cell growth, apoptosis, development and immune response, and is implicated in diverse type of malig...

    Authors: Jian Wu, Min Zhang, Omar Faruq, Eldad Zacksenhaus, Wenming Chen, Aijun Liu and Hong Chang

    Citation: Biomarker Research 2021 9:48

    Content type: Research

    Published on:

  4. miRNA-21 is among the most abundant and highly conserved microRNAs (miRNAs) recognized. It is expressed in essentially all cells where it performs vital regulatory roles in health and disease. It is also frequ...

    Authors: Ana E. Jenike and Marc K. Halushka

    Citation: Biomarker Research 2021 9:18

    Content type: Review

    Published on:

  5. A subset of men with metastatic prostate cancer (mPC) responds to immune checkpoint inhibitors, and there is an unmet need to predict those most likely to benefit. We characterized circulating tumor cells (CTC...

    Authors: Tian Zhang, Anika Agarwal, R. Garland Almquist, Daniella Runyambo, Sally Park, Elizabeth Bronson, Rengasamy Boominathan, Chandra Rao, Monika Anand, Taofik Oyekunle, Patrick Healy, Megan A. McNamara, Kathryn Ware, Jason A. Somarelli, Daniel J. George and Andrew J. Armstrong

    Citation: Biomarker Research 2021 9:14

    Content type: Rapid communication

    Published on: